EGFR signaling as a mechanism of resistance to CDK4/6 inhibitors in Palbociclib-resistant ER plus breast cancer cells

被引：0
|
作者：
Lypova, Nadiia [1 ]
Lanceta, Lilibeth [1 ]
Dougherty, Susan M. [1 ]
Chesney, Jason A. [1 ]
Imbert-Fernandez, Yoannis [1 ]
机构：
[1] Univ Louisville, Louisville, KY USA
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1772
引用
收藏
页数：2
相关论文
共 50 条
  • [1] EGFR signaling contributes to acquired resistance to CDK4/6 inhibitors in ER plus breast cancer cells in vitro and in vivo
    Lypova, Nadiia
    Lanceta, Lilibeth
    Daugherty, Susan
    Chesney, Jason
    Imbert-Fernandez, Yoannis
    CANCER RESEARCH, 2023, 83 (05)
  • [2] Metabolic reprogramming of ER plus breast cancer cells in response and resistance to the CDK4/6 inhibitor palbociclib
    Lorito, Nicla
    Bacci, Marina
    Smiriglia, Alfredo
    Parri, Matteo
    Malorni, Luca
    Di Leo, Angelo
    Chiarugi, Paola
    Morandi, Andrea
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (02) : 529 - 530
  • [3] Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER plus breast cancer
    Formisano, Luigi
    Lu, Yao
    Servetto, Alberto
    Hanker, Ariella B.
    Jansen, Valerie M.
    Bauer, Joshua A.
    Sudhan, Dhivya R.
    Guerrero-Zotano, Angel L.
    Croessmann, Sarah
    Guo, Yan
    Ericsson, Paula Gonzalez
    Lee, Kyung-Min
    Nixon, Mellissa J.
    Schwarz, Luis J.
    Sanders, Melinda E.
    Dugger, Teresa C.
    Cruz, Marcelo Rocha
    Behdad, Amir
    Cristofanilli, Massimo
    Bardia, Aditya
    O'Shaughnessy, Joyce
    Nagy, Rebecca J.
    Lanman, Richard B.
    Solovieff, Nadia
    He, Wei
    Miller, Michelle
    Su, Fei
    Shyr, Yu
    Mayer, Ingrid A.
    Balko, Justin M.
    Arteaga, Carlos L.
    NATURE COMMUNICATIONS, 2019, 10 (1)
  • [4] Mechanisms of resistance to CDK4/6 inhibition in ER plus breast cancer
    Lee, N. V.
    Eisele, K. J.
    Chionis, J.
    Yuan, J.
    Zhu, Z.
    Liu, C.
    Li, D.
    Olson, P. A.
    Fantin, V.
    Arndt, K. T.
    Shields, D. J.
    VanArsdale, T. L.
    CANCER RESEARCH, 2016, 76
  • [5] Characterization of resistance to the selective CDK4/6 inhibitor palbociclib in ER positive breast cancer
    Lenihan, C.
    Bouchekioua-Bouzaghou, K.
    Shia, A.
    Wilkes, E.
    Casado-Izguierdo, P.
    Cutillas, P.
    Schmid, P.
    CANCER RESEARCH, 2016, 76
  • [6] Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
    Luigi Formisano
    Yao Lu
    Alberto Servetto
    Ariella B. Hanker
    Valerie M. Jansen
    Joshua A. Bauer
    Dhivya R. Sudhan
    Angel L. Guerrero-Zotano
    Sarah Croessmann
    Yan Guo
    Paula Gonzalez Ericsson
    Kyung-min Lee
    Mellissa J. Nixon
    Luis J. Schwarz
    Melinda E. Sanders
    Teresa C. Dugger
    Marcelo Rocha Cruz
    Amir Behdad
    Massimo Cristofanilli
    Aditya Bardia
    Joyce O’Shaughnessy
    Rebecca J. Nagy
    Richard B. Lanman
    Nadia Solovieff
    Wei He
    Michelle Miller
    Fei Su
    Yu Shyr
    Ingrid A. Mayer
    Justin M. Balko
    Carlos L. Arteaga
    Nature Communications, 10
  • [7] Activation of the EGFR/RAS/p42,44 MAPK axis as a convergent mechanism of resistance to CDK4/6 inhibitors in ER plus breast cancer
    De Angelis, Carmine
    Cataldo, Maria Letizia
    Nardone, Agostina
    Veeraraghavan, Jamunarani
    Fu, Xiaoyong
    Nanda, Sarmistha
    Qin, Lanfang
    Sethunath, Vidyalakshmi
    Pereira, Resel
    Weigelt, Britta
    Reis-Filho, Jorge S.
    Rimawi, Mothaffar F.
    Jeselsohn, Rinath
    Osborne, Kent
    Schiff, Rachel
    CANCER RESEARCH, 2020, 80 (04)
  • [8] ESR1 mutations drive resistance to CDK4/6 inhibitors in ER plus Breast Cancer
    Chica-Parrado, M. Rosario
    Lin, Chang-Ching
    Jaeger, Ellen
    Harris, Michelle
    Guo, Lei
    Bikorimana, Emmanuel
    Napolitano, Fabiana
    Chao, Calvin
    Hanker, Ariella
    Arteaga, Carlos
    CANCER RESEARCH, 2024, 84 (09)
  • [9] The role of FGF/FGFR axis in resistance to SERDs and CDK4/6 inhibitors in ER plus breast cancer
    Mao, Pingping
    Kusiel, Justin
    Cohen, Ofir
    Wagle, Nikhil
    CANCER RESEARCH, 2018, 78 (04)
  • [10] Molecular determinants of resistance to CDK4/6 inhibition in ER plus breast cancer
    Luo, F.
    Cowley, G.
    Garraway, L.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S76 - S76
12345